Stay updated on Pyrotinib vs Docetaxel in HER2 NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pyrotinib vs Docetaxel in HER2 NSCLC Clinical Trial page.

Latest updates to the Pyrotinib vs Docetaxel in HER2 NSCLC Clinical Trial page
- Check3 days agoChange DetectedRecord history updated with a new revision entry (v3.3.4) and removal of the previous revision entry (v3.3.3); to avoid alerts for minor changes, set an alert condition.SummaryDifference0.1%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedNew entries in Record History include a Completed status dated 2025-12-19 and Study Status/Recruitment Status updates on 2025-12-18 (Revision: v3.3.3). Older status details and the HHS Vulnerability Disclosure line were removed.SummaryDifference2%

- Check53 days agoChange DetectedRevision v3.3.2 has been added to the Record History, and Revision v3.2.0 has been removed from the list.SummaryDifference0.1%

- Check60 days agoChange DetectedThe banner about a lapse in government funding and operating status (with references to cc.nih.gov and opm.gov) was removed. This is a site-wide notice rather than a change to the trial record details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.8%

- Check74 days agoChange DetectedVersion 5 (2023-03-07) was added to the history, updating Recruitment Status, Study Status, and Study Design. This revision reflects the trial's current activity and design details.SummaryDifference0.1%

- Check103 days agoChange Detected- Updated the page to v3.2.0 and added a government-operational status notice clarifying potential delays and open status of NIH Clinical Center. - Removed the previous version tag v3.1.0.SummaryDifference12%

Stay in the know with updates to Pyrotinib vs Docetaxel in HER2 NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pyrotinib vs Docetaxel in HER2 NSCLC Clinical Trial page.